Insulin resistance plays a major role in the pathogenesis of the metabolic syndrome. Inflammation is the leading cause of insulin resistance, and interleukin 10 (IL-10) is one of the anti-inflammatory cytokines. We conducted a case-control study to investigate the association between the IL-10 polymorphisms and the metabolic syndrome.
Methods
One thousand two hundred two unrelated subjects residing in southern Taiwan were retrospectively recruited from a community-based health screening program. Two hundred sixty subjects were defined as the metabolic syndrome (3-5 risk components) and 549 subjects as controls (0-1 risk component) on the basis of the Asian version of the Adult Treatment Panel III criteria. A functional IL-10 single nucleotide polymorphism (SNP; rs1800871) and 2 tagging SNPs (rs3790622, rs3021094) were genotyped by TaqMan method.
Results
We analyzed the association between the genotypes and the presence of the metabolic syndrome or metabolic traits by χ2 test and multivariant logistic regression. None of the IL-10 SNPs were found to be significantly related with the metabolic syndrome or its risk components. All the 3 SNPs were in single linkage disequilibrium block. Haplotype analysis did not yield significant association between IL-10 gene and the metabolic syndrome (global P = 0.88).
Conclusions
Because we used tagging SNPs and a modest clinical cohort, we concluded that the IL-10 gene polymorphisms may be unlikely to play an important role for the metabolic syndrome.
KekalainenP, SarlundH, PyoralaK, . Hyperinsulinemia cluster predicts the development of type 2 diabetes independently of family history of diabetes. Diabetes Care. 1999;22:86–92.
BarzilayJI, AbrahamL, HeckbertSR, . The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001;50:2384–2389.
8.
PradhanAD, MansonJE, RifaiN, . C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–334.
9.
MatsuzawaY.The metabolic syndrome and adipocytokines. FEBS Lett. 2006;580:2917–2921.
10.
QatananiM, LazarMA.Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 2007;21:1443–1455.
YamauchiT, KamonJ, WakiH, . The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–946.
ChanJL, HeistK, DePaoliAM, . The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest. 2003;111:1409–1421.
15.
NishidaM, MoriyamaT, SugitaY, . Interleukin-10 associates with adiponectin predominantly in subjects with metabolic syndrome. Circ J. 2007;71:1234–1238.
16.
MoorePE, LahiriT, LaporteJD, . Selected contribution: synergism between TNF-alpha and IL-1 beta in airway smooth muscle cells: implications for beta-adrenergic responsiveness. J Appl Physiol. 2001;91:1467–1474.
17.
KimHJ, HigashimoriT, ParkSY, . Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes. 2004;53:1060–1067.
18.
van ExelE, GusseklooJ, de CraenAJ, . Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes. 2002;51:1088–1092.
19.
EspositoK, PontilloA, GiuglianoF, . Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab. 2003;88:1055–1058.
20.
ChoiKM, RyuOH, LeeKW, . Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract. 2007;75:235–240.
21.
WestendorpRG, LangermansJA, HuizingaTW, . Genetic influence on cytokine production in meningococcal disease. Lancet. 1997;349:1912–1913.
Edwards-SmithCJ, JonssonJR, PurdieDM, . Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology. 1999;30:526–530.
24.
ScarpelliD, CardelliniM, AndreozziF, . Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in caucasian italian subjects. Diabetes. 2006;55:1529–1533.
25.
BassolsJ, BotasP, Moreno-NavarreteJM, . Environmental and genetic factors influence the relationship between circulating IL-10 and obesity phenotypes. Obesity (Silver Spring). 2010;18:611–618.
26.
UppermanJS, PillageG, SiddiqiMQ, . Dominance of high-producing interleukin 6 and low-producing interleukin 10 and interferon gamma alleles in glucose-6-phosphate dehydrogenase-deficient trauma patients. Shock. 2005;23:197–201.
27.
International HapMap Consortium.A haplotype map of the human genome. Nature. 2005;437:1299–1320.
28.
BarrettJC, FryB, MallerJ, . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–265.
29.
TurnerDM, WilliamsDM, SankaranD, . An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1–8.
30.
TzengJY, WangCH, KaoJT, . Regression-based association analysis with clustered haplotypes through use of genotypes. Am J Hum Genet. 2006;78:231–242.
31.
DeFronzoRA, FerranniniE.Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194.
32.
XuH, BarnesGT, YangQ, . Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–1830.
33.
PermanaPA, MengeC, ReavenPD.Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem Biophys Res Commun. 2006;341:507–514.
34.
HamdyO, PorramatikulS, Al-OzairiE.Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev. 2006;2:367–373.
35.
HenkinL, BergmanRN, BowdenDW, . Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods. Ann Epidemiol. 2003;13:211–217.
36.
FuentesL, RoszerT, RicoteM.Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages. Mediators Inflamm. 2010;2010:219583.
37.
RasouliN, KernPA.Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93:S64–S73.
38.
EspositoK, GiuglianoG, ScuderiN, . Role of adipokines in the obesity-inflammation relationship: the effect of fat removal. Plast Reconstr Surg. 2006;118:1048–1057; discussion 1058–1049.
39.
ManigrassoMR, FerroniP, SantilliF, . Association between circulating adiponectin and interleukin-10 levels in android obesity: effects of weight loss. J Clin Endocrinol Metab. 2005;90:5876–5879.
40.
KubeD, PlatzerC, vonKnethen A, . Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines. Cytokine. 1995;7:1–7.
41.
LimS, CrawleyE, WooP, . Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet. 1998;352:113.
42.
CrawleyE, KayR, SillibourneJ, . Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 1999;42:1101–1108.
43.
BradyJ, HayakawaY, SmythMJ, . IL-21 induces the functional maturation of murine NK cells. J Immunol. 2004;172:2048–2058.
